国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2013年
9期
1273-1275
,共3页
缬沙坦%雷公藤多苷%川芎嗪%DN
纈沙坦%雷公籐多苷%川芎嗪%DN
힐사탄%뢰공등다감%천궁진%DN
Valsartan%Tripterygium glucosides%Ligustrazine%Diabetic nephropathy
目的 观察缬沙坦联合雷公藤多苷、川芎嗪治疗糖尿病肾病(diabetic nephropathy,DN)蛋白尿的疗效和安全性.方法 选择66例DN患者[选择依据30 mg/24 h≤微量白蛋白排泄率(UAER)＜300mg/24 h,24 h尿蛋白≥1.0 g],将其分为对照组36例和观察组30例.对照组在常规基础治疗之上予缬沙坦治疗;观察组在对照组治疗基础之上加用雷公藤多苷及川芎嗪治疗.观察比较治疗前、后两组患者24h尿蛋白、尿白蛋白排泄率(urinary albumin excretion rate,UAER)、血肌酐(serum creatinine,SCr)及尿素氮(bloodurea nitrogen,BUN)、肝酶学改变、糖化血红蛋白(glycosylated hemoglobin,HbA1c)和血细胞计数.结果 治疗后观察组24 h尿蛋白、UAER下降明显,与对照组相比差异有统计学意义(P＜0.05).两组治疗前、后HbA1c、血肌酐、尿素氮、谷丙转氨酶酶和血常规比较差异均无统计学意义(P＞0.05).结论 在常规治疗的基础上,缬沙坦联合雷公藤多苷、川芎嗪治疗DN疗效显著,可有效降低患者蛋白尿水平,且安全性较好,值得在临床推广应用.
目的 觀察纈沙坦聯閤雷公籐多苷、川芎嗪治療糖尿病腎病(diabetic nephropathy,DN)蛋白尿的療效和安全性.方法 選擇66例DN患者[選擇依據30 mg/24 h≤微量白蛋白排洩率(UAER)＜300mg/24 h,24 h尿蛋白≥1.0 g],將其分為對照組36例和觀察組30例.對照組在常規基礎治療之上予纈沙坦治療;觀察組在對照組治療基礎之上加用雷公籐多苷及川芎嗪治療.觀察比較治療前、後兩組患者24h尿蛋白、尿白蛋白排洩率(urinary albumin excretion rate,UAER)、血肌酐(serum creatinine,SCr)及尿素氮(bloodurea nitrogen,BUN)、肝酶學改變、糖化血紅蛋白(glycosylated hemoglobin,HbA1c)和血細胞計數.結果 治療後觀察組24 h尿蛋白、UAER下降明顯,與對照組相比差異有統計學意義(P＜0.05).兩組治療前、後HbA1c、血肌酐、尿素氮、穀丙轉氨酶酶和血常規比較差異均無統計學意義(P＞0.05).結論 在常規治療的基礎上,纈沙坦聯閤雷公籐多苷、川芎嗪治療DN療效顯著,可有效降低患者蛋白尿水平,且安全性較好,值得在臨床推廣應用.
목적 관찰힐사탄연합뢰공등다감、천궁진치료당뇨병신병(diabetic nephropathy,DN)단백뇨적료효화안전성.방법 선택66례DN환자[선택의거30 mg/24 h≤미량백단백배설솔(UAER)＜300mg/24 h,24 h뇨단백≥1.0 g],장기분위대조조36례화관찰조30례.대조조재상규기출치료지상여힐사탄치료;관찰조재대조조치료기출지상가용뢰공등다감급천궁진치료.관찰비교치료전、후량조환자24h뇨단백、뇨백단백배설솔(urinary albumin excretion rate,UAER)、혈기항(serum creatinine,SCr)급뇨소담(bloodurea nitrogen,BUN)、간매학개변、당화혈홍단백(glycosylated hemoglobin,HbA1c)화혈세포계수.결과 치료후관찰조24 h뇨단백、UAER하강명현,여대조조상비차이유통계학의의(P＜0.05).량조치료전、후HbA1c、혈기항、뇨소담、곡병전안매매화혈상규비교차이균무통계학의의(P＞0.05).결론 재상규치료적기출상,힐사탄연합뢰공등다감、천궁진치료DN료효현저,가유효강저환자단백뇨수평,차안전성교호,치득재림상추엄응용.
Objective To observe the efficacy and safety of triple therapy with valsartan,tripterygium glucosides and ligustrazine in the treatment of proteinuria associated with diabetic nephropathy.Methods 66 patients with diabetic nephropathy (according to 300 mg / 24 h ＞ trace albumin discharge rate (UAER) or 30 mg / 24 h,24 h urine protein was 1.0 g) were selected as subject and then divided into a study group and a control group,36 for the control group and 30 for the study group.In addition to conventional treatment,the control group received valsartan and the study group received valsartan,tripterygium glucosides,and ligustrazine.24-h urine protein,urinary albumin discharge rate (UAER),serum creatinine (SCr) and urea nitrogen (BUN),liver zymology change,glycosylated hemoglobin (HbA 1 c) and blood count were observed in both groups before and after treatment and then were compared between the two groups.Results After treatment,24-h urine protein and UAER were declined significantly in the study group,as compared with the control group (P＜0.05),while levels of HbA1c,serum creatinine,blood urea nitrogen,cereal third transaminase enzyme and routine blood count had no statistical significance (P＞0.05) between the two groups before and after treatment.Conclusions In addition to conventional treatment,triple therapy with valsartan,tripterygium glucosides,and ligustrazine is effective and safe in the treatment of proteinuria associated with diabetic nephropathy,effectively reducing the level of proteinuria in patients.It is safe and worth popularizing clinically.
